News | Vascular Closure Devices | November 09, 2021

Plug-based Vascular Closure Following TAVR Offers Shorter Hemostasis Time Than Suture-based Devices

But results from the CHOICE-CLOSURE Trial also show plug-based systems have more vascular complications

The Teleflex Manta large bore vascular closure device #TCT2021

The Teleflex Manta large bore vascular closure device.


November 9, 2021 — Results from the largest randomized trial available comparing different closure device strategies following transcatheter aortic valve replacement (TAVR) found that a plug-based vascular closure technique had a shorter time to hemostasis, but a higher rate of access-site or access-related vascular complications.

Findings were reported at the 2021 Transcatheter Cardiovascular Therapeutics (TCT) annual scientific symposium of the Cardiovascular Research Foundation (CRF). The study was also published simultaneously in Circulation.[1]

TAVR is commonly used for elderly patients with severe aortic stenosis (AS). However, vascular complications after transfemoral TAVR contribute significantly to morbidity and mortality and are commonly related to the arterial access site. Several approved percutaneous vascular closure device (VCD) strategies are available and are being used interchangeably in routine clinical practice.

The CHOICE-CLOSURE trial was an investigator-initiated, multicenter trial that randomized patients with severe symptomatic AS and acceptable transfemoral vascular access to either the pure plug-based MANTA VCD technique or the primary suture-based ProGlide technique. Between June 2020 and June 2021, 516 patients undergoing transfemoral TAVR were enrolled and randomized 1:1 at three German centers. The plug-based strategy was used in 258 patients and 258 patients received the suture-based vascular closure strategy.

The primary endpoint was the rate of access-site or access-related vascular complications according to the Valve Academic Research Consortium (VARC)-2 definition during index hospitalization. The event rate for the plug-based technique was 19.4% compared to 12.0% in the suture-based technique (RR 1.61, 95% CI 1.07-2.44, p=0.029). Secondary endpoints included device failure, time to hemostasis and access-site related bleeding at 30 days. Time to hemostasis was lower with the plug-based technique (80 seconds versus 240 seconds, p<0.001). The 30-day outcomes for access-site or access-related vascular complications, access-site or access-related bleeding and/or VCD failure was 19.8% for the plug-based group compared to 12.8% for the suture-based group (p=0.043).

“With the introduction of large-bore plug-based devices, operators now have an alternative to the classical suture-based technique,” said Mohamed Abdel-Wahab, M.D., Ph.D., professor of interventional cardiology, consultant cardiology and head of department of structural heart disease at the Heart Center Leipzig, University of Leipzig. “However, randomized comparisons of these technique are scarce. Results from CHOICE-CLOSURE indicate that both techniques have infrequent severe complications, with low and comparable mortality and life-threatening bleeding rates. While associated with a shorter time to hemostasis, the plug-based technique did have a significantly higher rate of access-site or access-related vascular complications.”

The study was funded by Helios Kliniken GmbH. Prof. Abdel-Wahab reported consulting fees/honoraria from Boston Scientific and Medtronic

Links to All the TCT 2021 Late-Breaking Clinical Trials

 

Reference:
1. Mohamed Abdel-Wahab, Philipp Hartung, Oliver Dumpies,, et al. Comparison of a Pure Plug-Based versus a Primary Suture-Based Vascular Closure Device Strategy for Transfemoral Transcatheter Aortic Valve Replacement: The CHOICE-CLOSURE Randomized Clinical Trial. Circulation. Originally published 5 Nov. 2021. https://doi.org/10.1161/CIRCULATIONAHA.121.057856Circulation. 2021;0
 

 


Related Content

News | TCT

Oct. 11, 2024 – As the pace of change accelerates in healthcare, the most pressing questions in cardiovascular medicine ...

Home October 16, 2024
Home
News | TCT

November 9, 2023 — Medinbox, a global provider of video integrated collaboration systems for interventional rooms and ...

Home November 09, 2023
Home
News | TCT

October 30, 2023 — Shockwave Medical, Inc., which develops technologies for the treatment of cardiovascular disease, has ...

Home October 30, 2023
Home
News | TCT

October 26, 2023 — The Society of Thoracic Surgeons and the European Association for Cardiothoracic Surgeons have issued ...

Home October 26, 2023
Home
News | TCT

October 26, 2023 — A new study presented at TCT 2023 revealed inequities in access to mechanical circulatory support in ...

Home October 25, 2023
Home
News | TCT

October 25, 2023 — Elixir Medical, developer of novel cardiovascular technologies, announced positive six-month clinical ...

Home October 25, 2023
Home
News | TCT

October 25, 2023 — Medtronic plc, a global leader in healthcare technology, announced four-year results from the Evolut ...

Home October 25, 2023
Home
News | TCT

October 25, 2023 — Information on a new double lumen catheter was presented by Nabil Dib, MD, MSc, FACC, FESC, during ...

Home October 25, 2023
Home
News | TCT

October 25, 2023 — For its novel multi-lumen stent system for interventional adjustment of pulmonary blood flow in ...

Home October 25, 2023
Home
Feature | TCT | By Melinda Taschetta-Millane

Innovation. Connection. Inspiration. The Transcatheter Cardiovascular Therapeutics (TCT) 2023 conference, the ...

Home October 20, 2023
Home
Subscribe Now